Sangamo Therapeutics (SGMO) Stock
Gene editing biotech developing treatments for rare diseases. Here's the price, business snapshot, and what's worth knowing about Sangamo Therapeutics in September 2026.
Sangamo Therapeutics (SGMO) is a clinical‑stage biotechnology company focused on genomic medicines, notably zinc finger nuclease (ZFN) gene editing and gene regulation technologies. With a market capitalisation of about $194.5m, Sangamo is relatively small and its value is driven by clinical trial readouts, partnerships and licensing outcomes rather than steady revenues. The company has multiple programmes in rare genetic diseases and immuno‑oncology, often advancing through co‑development deals with larger partners. Investing in Sangamo typically means exposure to binary clinical and regulatory catalysts, significant research and development spend, and potential dilution if additional financing is needed. While the technology has scientific promise, clinical success is uncertain and timelines can be long. This summary is educational and not personal advice; investors should consider their risk tolerance, review financials and seek independent financial advice before investing.
Why You’ll Want to Watch This Stock
Genome editing focus
Sangamo’s zinc finger platform is a distinctive science play; it can create upside if clinical results succeed, though outcomes are uncertain.
Clinical catalysts ahead
Trial readouts and regulatory moves tend to move the share price significantly; this creates opportunity and volatility.
Partnerships and funding
Collaborations and licensing deals can de‑risk programmes or provide cash, but the company may still need financing, which can dilute shareholders.
